Applications of machine learning in drug discovery and development.

Journal: Nature reviews. Drug discovery
Published Date:

Abstract

Drug discovery and development pipelines are long, complex and depend on numerous factors. Machine learning (ML) approaches provide a set of tools that can improve discovery and decision making for well-specified questions with abundant, high-quality data. Opportunities to apply ML occur in all stages of drug discovery. Examples include target validation, identification of prognostic biomarkers and analysis of digital pathology data in clinical trials. Applications have ranged in context and methodology, with some approaches yielding accurate predictions and insights. The challenges of applying ML lie primarily with the lack of interpretability and repeatability of ML-generated results, which may limit their application. In all areas, systematic and comprehensive high-dimensional data still need to be generated. With ongoing efforts to tackle these issues, as well as increasing awareness of the factors needed to validate ML approaches, the application of ML can promote data-driven decision making and has the potential to speed up the process and reduce failure rates in drug discovery and development.

Authors

  • Jessica Vamathevan
    European Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge, UK. jessicav@ebi.ac.uk.
  • Dominic Clark
    European Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge, UK.
  • Paul Czodrowski
    Technical University of Dortmund, Dortmund, Germany.
  • Ian Dunham
    European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD UK ; Centre for Therapeutic Target Validation, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD UK.
  • Edgardo Ferran
    European Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge, UK.
  • George Lee
    Case Western Reserve University, Department of Biomedical Engineering, Cleveland, OH, United States of America.
  • Bin Li
    Department of Magnetic Resonance Imaging (MRI), Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Anant Madabhushi
    Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio.
  • Parantu Shah
    EMD Serono R&D Institute, Billerica, MA, USA.
  • Michaela Spitzer
    Wellcome Trust Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3JR, UK; Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON L8N 3Z5, Canada.
  • Shanrong Zhao
    Pfizer Worldwide Research and Development, Cambridge, MA, USA.